 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...131132133134135136137138139140141...236237» |
- || Avastin (bevacizumab) / Roche
Clinical, P2 data, Journal: Phase II Trial Of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer. (Pubmed Central) - Jun 22, 2021
The study failed to meet the required 3 pCRs in the first 18 pts. The DFS in this population is encouraging and supports the hypothesis that select pts with rectal cancer may be spared from radiation.
- || cisplatin / Generic mfg.
Review, Journal: The Evolving Role of Systemic Therapy in the Primary Treatment of Sinonasal Cancer. (Pubmed Central) - Jun 22, 2021
Multimodality trials are ongoing to test the activity of induction chemotherapy followed by locoregional curative treatment. A deeper knowledge of the molecular deregulations of these diseases could help in identifying targeted therapies.
- || irinotecan / Generic mfg.
Biomarker, Clinical, Journal: Prognostic Role of the Platelet-to-Lymphocyte Ratio for Patients With Metastatic Colorectal Cancer Treated With Aflibercept. (Pubmed Central) - Jun 22, 2021
A deeper knowledge of the molecular deregulations of these diseases could help in identifying targeted therapies. A low pretreatment PLR might be a predictor of aflibercept efficacy in patients with mCRC and may be clinically useful for selecting patient responders.
- || piperacillin sodium/tazobactam sodium / Generic mfg., methotrexate / Generic mfg.
Clinical, Journal: Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient. (Pubmed Central) - Jun 22, 2021
A low pretreatment PLR might be a predictor of aflibercept efficacy in patients with mCRC and may be clinically useful for selecting patient responders. Severe MTX-related toxicity, caused by drug-drug interaction, suggests that the concomitant use of high-dose MTX and high-dose piperacillin-tazobactam should be avoided generally.
- || 5-fluorouracil / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Case report on 5-fluorouracil induced cerebrovascular accident. (Pubmed Central) - Jun 22, 2021
Severe MTX-related toxicity, caused by drug-drug interaction, suggests that the concomitant use of high-dose MTX and high-dose piperacillin-tazobactam should be avoided generally. The clinicians and clinical pharmacists must be aware about the potential of 5-FU to induce rare side effects such as CVA even in low risk patients in order to avoid permanent harm to the patient.
- || Cyramza (ramucirumab) / Eli Lilly
Clinical, P1 data, Journal, Combination therapy: Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study. (Pubmed Central) - Jun 22, 2021
There were no unexpected safety findings with ramucirumab plus FOLFOX4 based on the known safety and toxicity of this regimen. The combination was not sufficiently tolerated in patients with advanced HCC at the specified dose and schedule.
- ||| oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
Clinical, Journal, Adverse events: Tolerability and Adverse Events of Adjuvant Chemotherapy for Rectal Cancer in Patients With Diverting Ileostomy. (Pubmed Central) - Jun 22, 2021
Completion rate of ACT in patients with diverting ileostomy was lower than that of colorectal cancer patients in the previous studies. UFT/LV may be a more tolerable regimen than Capecitabine or CAPOX in colorectal cancer patients with diverting ileostomy.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Efficacy of FOLFOX in patients with aggressive pancreatic NETs after prior capecitabine/temozolomide. (Pubmed Central) - Jun 22, 2021
FOLFOX chemotherapy has robust activity in patients with aggressively progressive, heavily pretreated pancreatic NETs, a setting where few, if any, other options are likely to be effective. Durations of response, however, are relatively short, and new treatments are urgently needed for patients with aggressive transformation of pancreatic NETs.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, P2 data, Journal: Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial. (Pubmed Central) - Jun 22, 2021
Objective response rates, overall survival, and progression-free survival were improved in the cetuximab group when compared with the modified FOLFOXIRI group. Addition of cetuximab to modified FOLFOXIRI increased the rate of no evidence of disease achieved, and this combination could be an option of conversion regimen for molecularly selected patients with initially technically unresectable colorectal liver-limited metastasis.
- | Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
Journal: FOLFOXIRI + bevacizumab versus FOLFOX + panitumumab for metastatic left sided RAS/BRAF wild type colorectal cancer: Which "side" are you on? (Pubmed Central) - Jun 22, 2021
The study accompanying this commentary presents a propensity score adjusted analysis using information from five previous randomized trials and provides best available evidence comparing these regimens. We will discuss their findings and how they fit in current treatment paradigms.
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Retrospective data, Journal: Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer. (Pubmed Central) - Jun 22, 2021
We will discuss their findings and how they fit in current treatment paradigms. Although pathological responses were comparable between two groups, mFOLFOXIRI tended to be more toxic compared to XELOX/SOX as NAC for LARC.
- | docetaxel / Generic mfg.
Journal: CROSS or FLOT in Distal Esophageal and Gastroesophageal Cancer. (Pubmed Central) - Jun 22, 2021
To compare the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) and continuous infusion 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) protocols administered in distal esophageal and gastroesophageal junction (GEJ) tumors in terms of effectiveness and toxicity...CROSS and FLOT protocols contributed to survival similarly in patients with GEJ ADC, hematological side effects were more pronounced in patients receiving CRT. Key Words: GEJ cancer, Esophageal cancer, Cross, Flot.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Clinical, Journal: Immune-modulating Effect of Korean Red Ginseng by Balancing the Ratio of Peripheral T Lymphocytes in Bile Duct or Pancreatic Cancer Patients With Adjuvant Chemotherapy. (Pubmed Central) - Jun 22, 2021
Key Words: GEJ cancer, Esophageal cancer, Cross, Flot. The ginseng group, which received Korean Red ginseng daily during adjuvant chemotherapy, showed higher levels of CD4 T lymphocytes and CD4/CD8 T lymphocyte ratio after chemotherapy.
- || docetaxel / Generic mfg.
Clinical, Retrospective data, Journal: Predictive Significance of Ki-67 and Platelet Lymphocyte Ratio in Patients with Gastric Cancer Receiving Neoadjuvant FLOT Chemotherapy. (Pubmed Central) - Jun 22, 2021
Ki-67 is an independent prognostic marker for OS in gastric cancer. Key Words: FLOT, Gastric cancer, Ki-67, Platelet lymphocyte ratio.
- | Cyramza (ramucirumab) / Eli Lilly, Avastin (bevacizumab) / Roche
Journal, Benefit-risk assessment: Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer. (Pubmed Central) - Jun 22, 2021
Key Words: FLOT, Gastric cancer, Ki-67, Platelet lymphocyte ratio. As a third-line treatment for mCRC, F-RAM/AFL should be prioritized over TAS-102 in terms of efficacy; however, the risk of AEs should be considered.
- | oxaliplatin / Generic mfg.
Trial primary completion date: 2 Versus 6 Hour Oxaliplatin Infusions in Patients with Gastrointestinal Cancers (clinicaltrials.gov) - Jun 22, 2021
P2, N=60, Recruiting, Sponsor: Emory University
As a third-line treatment for mCRC, F-RAM/AFL should be prioritized over TAS-102 in terms of efficacy; however, the risk of AEs should be considered. Trial primary completion date: Mar 2021 --> Nov 2022
- || Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Metastases: PRODIGE 59 - DURIGAST: Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jun 22, 2021
P2, N=107, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Trial primary completion date: Mar 2021 --> Nov 2022 Recruiting --> Active, not recruiting
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial initiation date, HEOR, Metastases: HOLIPANC: Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Jun 22, 2021
P2, N=150, Not yet recruiting, Sponsor: University of Cologne
Recruiting --> Active, not recruiting Initiation date: Jan 2021 --> Aug 2021
- ||| Vectibix (panitumumab) / Amgen
Trial completion, Enrollment change: OPALO: FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status (clinicaltrials.gov) - Jun 21, 2021
P2, N=20, Completed, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Initiation date: Jan 2021 --> Aug 2021 Active, not recruiting --> Completed | N=80 --> 20
- ||| Xpovio (selinexor) / Karyopharm
Enrollment change: SPRINT: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (clinicaltrials.gov) - Jun 21, 2021
P1/2, N=120, Recruiting, Sponsor: Karyopharm Therapeutics Inc
Active, not recruiting --> Completed | N=80 --> 20 N=80 --> 120
- | Avastin (bevacizumab) / Roche
Biomarker, Trial primary completion date: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Jun 18, 2021
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=80 --> 120 Trial primary completion date: Jun 2021 --> Oct 2021
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: METHEP-2: Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases (clinicaltrials.gov) - Jun 18, 2021
P2, N=256, Completed, Sponsor: UNICANCER
Trial primary completion date: Jun 2021 --> Oct 2021 Active, not recruiting --> Completed
- ||| New P1 trial: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (clinicaltrials.gov) - Jun 18, 2021
P1, N=80, Not yet recruiting, Sponsor: Hoffmann-La Roche
- |||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen
Trial completion date, Trial primary completion date: STRATEGIC-1: Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 16, 2021
P3, N=474, Recruiting, Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Active, not recruiting --> Completed Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Dec 2019 --> Jun 2021
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma-In Reply. (Pubmed Central) - Jun 16, 2021
Trial completion date: Dec 2019 --> Jun 2021 | Trial primary completion date: Dec 2019 --> Jun 2021 No abstract available
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma. (Pubmed Central) - Jun 16, 2021
No abstract available No abstract available
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Tumor Lysis Syndrome in a Patient With Gastric Adenocarcinoma. (Pubmed Central) - Jun 16, 2021
This case highlights the importance of early recognition of TLS in patients with gastric cancer. Initiation of early treatment can reduce the high morbidity and mortality associated with this oncologic emergency.
- | Enrollment change: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients (clinicaltrials.gov) - Jun 16, 2021
P3, N=702, Recruiting, Sponsor: Prof. Dr. med. Claus R
Initiation of early treatment can reduce the high morbidity and mortality associated with this oncologic emergency. N=40 --> 702
- | New P3 trial: PREOPANC-3: Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer (clinicaltrials.gov) - Jun 16, 2021
P3, N=378, Not yet recruiting, Sponsor: Erasmus Medical Center
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Clinical, Journal: Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancer. (Pubmed Central) - Jun 16, 2021
We retrospectively reviewed 76 consecutive patients with metastatic pancreatic adenocarcinoma who underwent mFOLFIRINOX or S-1 treatment as a second-line chemotherapy after gemcitabine plus nab-paclitaxel (GnP) failure at our department between December 2014 and February 2019...mFOLFIRINOX as a second-line regimen contributed to favorable treatment outcomes, but induced more frequent adverse events than S-1. On multivariate analyses, mFOLFIRINOX was identified as an independent factor with favorable PFS, suggesting that mFOLFIRINOX could be a promising treatment option for patients with GnP failure.
- | irinotecan / Generic mfg.
New trial: XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study) (clinicaltrials.gov) - Jun 15, 2021
P=N/A, N=24, Not yet recruiting, Sponsor: Guangzhou University of Traditional Chinese Medicine
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Pseudomyxoma retroperitonei masquerading as a psoas abscess. (Pubmed Central) - Jun 12, 2021
Our treatment plan after ileostomy was cytoreductive surgery along with adjuvant radiotherapy (40 Gy in 20 fractions) with chemotherapy (5-fluorouracil and folinic acid given for 30 weeks, once a week). However, after ileostomy, the patient refused further treatment, citing financial reasons.
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: NCI-2018-00737: Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 11, 2021
P2, N=6, Completed, Sponsor: M.D. Anderson Cancer Center
However, after ileostomy, the patient refused further treatment, citing financial reasons. Recruiting --> Completed | N=44 --> 6 | Trial completion date: Dec 2035 --> May 2021 | Trial primary completion date: Dec 2035 --> May 2021
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal: FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. (Pubmed Central) - Jun 11, 2021
P3
The superior response associated with cetuximab may particularly benefit patients with symptomatic tumours or borderline-resectable metastases. CLINICALTRIALS.
- || aspirin / Generic mfg.
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin. (Pubmed Central) - Jun 11, 2021
The aim of this study was to determine the effect of folinic acid, 5-FU and oxaliplatin (FOLFOX) as a single agent and aspirin plus FOLFOX in various combinations on the aforementioned proteins in human CRC, SW480 cell line and rat models of N-Methyl-N-Nitrosourea (NMU)-induced CRC...The mechanistic rational of these effects underscores the importance of expanded concept of possible aspirin combination therapy with FOLFOX sequentially in future CRC management. Validation of our findings through randomized clinical trials of aspirin plus FOLFOX sequentially in patients with CRC is therefore warranted.
- | Erbitux (cetuximab) / Eli Lilly
New trial, Metastases: Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy (clinicaltrials.gov) - Jun 11, 2021
P, N=51, Not yet recruiting, Sponsor: Shanghai Minimally Invasive Surgery Center
- | Enrollment open, Trial completion date, Trial primary completion date, Metastases: I-FLOAT: Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies (clinicaltrials.gov) - Jun 10, 2021
P1, N=54, Recruiting, Sponsor: University of Chicago
Validation of our findings through randomized clinical trials of aspirin plus FOLFOX sequentially in patients with CRC is therefore warranted. Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> May 2027 | Trial primary completion date: Sep 2023 --> Jun 2022
- || irinotecan / Generic mfg.
Clinical, Journal: Association of losartan with outcomes in metastatic pancreatic cancer patients treated with chemotherapy. (Pubmed Central) - Jun 10, 2021
Our findings should be validated in a larger cohort to confirm if the benefit of losartan and FOLFIRINOX seen in a neoadjuvant setting for locally advanced cancer also applies to metastatic cancer. This research adds to growing data on the efficacy of angiotensin receptor blocking drugs as adjunctive treatment in addition to chemotherapy in pancreatic cancer with specific focus on metastatic disease.
- |||| Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial primary completion date, Metastases: Avenger 500: Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Jun 9, 2021
P3, N=528, Active, not recruiting, Sponsor: Rafael Pharmaceuticals Inc.
This research adds to growing data on the efficacy of angiotensin receptor blocking drugs as adjunctive treatment in addition to chemotherapy in pancreatic cancer with specific focus on metastatic disease. Trial primary completion date: Apr 2021 --> Dec 2021
- |||||||||| Solucin (177Lu-edotreotide) / ITM Isotopen Technologien Munchen
New P3 trial, Patient reported outcomes: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (clinicaltrials.gov) - Jun 9, 2021
P3, N=202, Not yet recruiting, Sponsor: ITM Solucin GmbH
- || Clinical, Journal: Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer. (Pubmed Central) - Jun 9, 2021
In contrast, the naive observational analysis suggested that a shortened duration of CAPOX was significantly associated with worse survival (HR, 3.33; 95% CI, 1.04-10.65). In this study, the explicit emulation of a target trial better approximated results from an analogous well-conducted randomized clinical trial.
- | Imkeldi (imatinib) / Shorla Oncology
Trial primary completion date, IO biomarker: AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 8, 2021
P3, N=700, Recruiting, Sponsor: Children's Oncology Group
In this study, the explicit emulation of a target trial better approximated results from an analogous well-conducted randomized clinical trial. Trial primary completion date: Jun 2028 --> Mar 2028
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Trial primary completion date, Combination therapy: NEO-Nal- IRI: A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jun 7, 2021
P2, N=53, Recruiting, Sponsor: University of Florida
Trial primary completion date: Jun 2028 --> Mar 2028 Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
- || Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Monotherapy, IO biomarker: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Jun 7, 2021
P1b/2, N=1113, Recruiting, Sponsor: Amgen
Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Sep 2021 --> Sep 2022 Trial completion date: Nov 2025 --> Feb 2028 | Trial primary completion date: Jun 2023 --> Jan 2024
- ||| Enrollment closed, Enrollment change, Metastases: PANTHEON: A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy (clinicaltrials.gov) - Jun 4, 2021
P2, N=67, Active, not recruiting, Sponsor: AIO-Studien-gGmbH
Trial completion date: Nov 2025 --> Feb 2028 | Trial primary completion date: Jun 2023 --> Jan 2024 Recruiting --> Active, not recruiting | N=204 --> 67
- |||| leucovorin calcium / Generic mfg.
Clinical, Adverse events: #EULAR2021 POS0227 recs all patients try subQ MTX before bDMARD. Mirza et al: ⬆️ efficacy & ⬇️side effects with subQ. May not be for all pts, but subQ ⬆️ efficacy than high-dose PO MTX. ⬇️ GI side effects, but ⬆️ ulcers/hair loss (use folate/leucovorin for this) @RheumNow (Twitter) - Jun 4, 2021
- || irinotecan / Generic mfg.
Review, Journal, IO biomarker: KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas. (Pubmed Central) - Jun 3, 2021
Overall, the KRAS mutation can drive an immunosuppression in pancreatic ductal adenocarcinomas or in colorectal carcinomas, but this mechanism is not true in KRAS-mutant lung adenocarcinomas, especially in the presence of TP53 inactivation. As a result, the response of these adenocarcinomas to checkpoint inhibitors will vary.
- | irinotecan / Generic mfg.
Journal: Data Driven Mathematical Model of FOLFIRI Treatment for Colon Cancer. (Pubmed Central) - Jun 3, 2021
For instance, patients in cluster 3 with the highest T-reg/T-helper ratio respond better to the FOLFIRI treatment, while patients in cluster 2 with the lowest T-reg/T-helper ratio resist the treatment. Moreover, we use ROC curve to validate the model using the tumor status of the patients at their follow up, and the model predicts well for the earlier follow up days.
- | oxaliplatin / Generic mfg.
Journal: Unexpected Ca-mobilization of oxaliplatin via H1 histamine receptors. (Pubmed Central) - Jun 2, 2021
Last, activation of H1 via either histamine or oxaliplatin activates TRPV1 receptors, a mechanism that has been associated with itch. These data, together with literature data that has shown that anti-histamine agents reduce the incidence of oxaliplatin-induced hypersensitivity, may provide a molecular mechanism of this side effect in oncological patients.
- || Vectibix (panitumumab) / Amgen, Takeda
Clinical, Journal: A prospective, single-arm, multicenter trial of neoadjuvant chemotherapy with mFOLFOX6 plus panitumumab without radiotherapy for locally advanced rectal cancer. (Pubmed Central) - Jun 2, 2021
Neoadjuvant chemotherapy of mFOLFOX6 plus panitumumab without radiotherapy resulted in a low pCR rate but a high PR rate, low local recurrence rate, and good long-term outcome, suggesting that this treatment strategy may be a viable option for patients unable or unwilling to receive radiotherapy. The trial was registered with the UMIN Clinical Trials Registry, number 000006039.